Fig. 2: ERK5 kinase activity confers resistance to TRAIL-induced apoptosis in cancer cells. | Cell Death & Disease

Fig. 2: ERK5 kinase activity confers resistance to TRAIL-induced apoptosis in cancer cells.

From: MAP kinase ERK5 modulates cancer cell sensitivity to extrinsic apoptosis induced by death-receptor agonists

Fig. 2: ERK5 kinase activity confers resistance to TRAIL-induced apoptosis in cancer cells.The alternative text for this image may have been generated using AI.

A Active ERK5 protects AN3CA EC cells to TRAIL-induced apoptosis. AN3CA EC cells were transfected with either ERK5 or a ERK5 kinase-dead mutant (D200A, ERK5-KD) together with a constitutively active form of MEK5 (MEK5-DD). Twenty-four hours after transfection cells were treated with 25 ng/ml TRAIL (8 h), and apoptosis was analyzed by flow cytometry (Annexin-V and PI staining). Left panel shows representative results of flow cytometry analysis. Right histograms show the quantification of apoptotic cells (early apoptotic Annexin-V + /PI- and late apoptotic Annexin-V + /PI+ cells). B, C ERK5 kinase activity impairs caspase-8 activation in response to TRAIL in AN3Ca (B) and Ishikawa (C) cells. Immunoblot analysis. Right histograms show the quantification of cleaved caspase-8 and −3 bands (mean ± SD, n = 3 independent biological experiments, one-way ANOVA followed by Bonferroni multiple comparison test). ***p < 0.001.

Back to article page